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Abstract
We have performed a comparative ultrasequencing study of multiple colorectal lesions ob-
tained simultaneously from four patients. Our data show that benign lesions (adenomatous
or hyperplastic polyps) contain a high mutational load. Additionally multiple synchronous co-
lorectal lesions show non overlapping mutational signatures highlighting the degree of het-
erogeneity between multiple specimens in the same patient. Observations in these cases
imply that considering not only the number of mutations but an effective oncogenic combi-
nation of mutations can determine the malignant progression of colorectal lesions.
Introduction
Our current understanding of colorectal cancer assumes that its pathogenesis includes a pro-
gressive accumulation of genomic changes at multiple stages. Thus, initiating events, such as
driver mutations affecting APC or KRAS genes, are followed by additional alterations in specif-
ic genes such as p16 and p53 [1] and signalling pathways including WNT, MAPK, GNAS or
TGFB that, over time, will shape the genomic conditions that drive a pre-malignant lesion to-
wards cancer [2–4]. Thus, premalignant lesions such as colorectal adenomas feature mutation-
al events in APC, BRAF, KRAS and other genes [2, 5]. As the disease progresses, colorectal
adenocarcinoma specimens can also accumulate mutations in genes such as p53 and FBXW7
as well as in MAPK, TGFB, PI3K and DNA mismatch-repair pathways [3]. However, the ques-
tion of whether somatic mutations accumulate in the adenoma-carcinoma sequence in the
same patient remains to be investigated.
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Here we have sequenced whole exomes of multiple lesions in four non-MSI colorectal can-
cer patients corresponding to different adenoma and adenocarcinoma specimen samples taken
during the same endoscopic procedure. Our first finding was that adenomas contained a large
number of mutations that, in general were reduced but still comparable, with the frequency
found in colorectal cancer samples. Additionally, different adenoma lesions within the same
patient were strikingly heterogeneous. Analysis of the mutation frequency also showed that a
large majority of the mutations found in adenoma samples were subclonal, and probably pas-
senger mutation events.
Results and Discussion
We characterized the genomic variants in a series of untreated colorectal lesions that included
adenocarcinomas, adenomas and hyperproliferative polyps taken simultaneously by endoscop-
ic resection, along with normal mucosa, which was used as a control (S1 Table). The topologies
of the lesions of each patient are shown in Figs. 1a, 2a, 3a and 3b and the clinical characteristics
are summarised in Table 1. We generated two paired-end 75-bp whole exome sequencing li-
braries and sequenced them using an Illumina HiSeq2000 instrument, which allowed us to
map an average of ~102 million reads per sample. Under these conditions, the mean coverage
of the target sequenced was 99X (78X-141X) with a mean of 92.1% (89.8–95.9) of targeted
bases with at least 15X coverage (S1 Table). Somatic variants were identified using the SAM-
tools suite. Additionally, we used RAMSES software [6] to call potential mutations showing
minimum independent multi-aligner evidence that enabled us to identify subclonal variants
present in at least 5% of the reads. We also performed a secondary analysis in a selection of
genes with known biological activity that confirmed specific mutations in up to 76.5% of those
genes with a mutational percentage above 15% in each sample of our primary analysis (Figs. 1b
and 2b and S1 Fig. and S2 Table). Using the data obtained in our primary analysis and aligned
with previous observations in colorectal lesions [5], we observed that most mutations were
C>T/G>A changes that occurred in CpG in up to 75% of the cases (Fig. 4, and S5 Table). In
addition, we reproduced these results using the validated data from the secondary analysis (S2
Fig.). A detailed description of the main findings is included in table 2 and S1–S5 Tables. We
decided to focus on those alterations that could potentially induce changes in the expression or
activity of the proteins including amino acid changing or truncating mutations. Analysing
their incidence, we found that most but not all benign lesions (adenoma or hyperproliferative
polyp) contained less genomic alterations than the colorectal cancer specimens (Figs. 1b, 2b, 3a
and 3b and table 2); a mutational rate similar to that described by the TCGA network for the
non-hypermutated colorectal adenocarcinoma samples [3]. Using this approach we were able
to detect one or multiple distinct gene alterations affecting APC in 6 of the 8 adenomas ana-
lysed, thereby underlining the relevance of the APC gene inactivation in the genesis of colorec-
tal adenomas. In the same line of evidence, we observed that these benign lesions lacked
mutations in genes or pathways considered essential in colorectal cancer [3], with the possible
exception of PIK3CG in the adenoma-2 case (Fig. 2c) or KRAS and NRAS mutations found in
adenomas-4B and 4C (Fig. 3f). On the other hand, we noticed that a number of mutations
found in the adenocarcinomas affected oncogenes such as GHR and INSR (Fig. 1c) or KRAS
and ERBB4 (Fig. 2c). These are well known for their ability to activate MAPK signalling. We
were able to detect them alongside other somatic mutations affecting SMAD genes (TGFB sig-
nalling, Fig. 2c and Fig. 3e) or adenylyl cyclases such as ADCY2 (Fig. 1c) and ADCY1 (Fig. 2c)
that participate in the COX2-PGE2-PR-GNAS signalling axis (reviewed in [7]). When compar-
ing the mutational spectrum of the multiple samples from the same patient, we did not find a
single recurrent mutation, which in addition to the multiple and non-recurrent alterations
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Fig 1. Mutation analysis of patient 1. A) Scheme showing an approximate representation of the location of each lesion analysed. The distance (*, in cms)
from the pectineal line (red dots) is shown. B) Mutational index (number of mutations/Mb) found in the indicated sample from the primary NGS analysis. H&E
pictures are representative of each lesion studied by NGS. C) Validated mutations found in a secondary targeted NGS analysis of the indicated samples.
Chrom: chromosome; %mutated: percentage of mutant nucleotides found in the corresponding gene within the same sample.
doi:10.1371/journal.pone.0119946.g001
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Fig 2. Mutation analysis of patient 2. A) Scheme showing an approximated representation of the location of each lesion analysed. The distance (*, in cms)
from the pectineal line (red dots) is shown. B) Mutational index (number of mutations/Mb) found in the indicated sample from the primary NGS analysis. H&E
pictures are representative of each lesion studied by NGS. C) Validated mutations found in a secondary targeted NGS analysis of the indicated samples.
Chrom: chromosome; %mutated: percentage of mutant nucleotide found in the corresponding gene within the same sample.
doi:10.1371/journal.pone.0119946.g002
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found in APC, suggests an independent origin of the multiple adenomas and adenocarcinoma
in the same patient. In this respect, we could detect individual lesions like for example adeno-
ma-30 (Fig. 1), carrying different mutations in APC detected at different percentages (14% and
51%). This may reflect a degree of subclonal activity that is not exclusive to adenomas, since
adenocarcinoma-2 (Fig. 2) also harboured two distinct APC mutations in 10.9% and 10.4% of
the alleles read. Moreover, our observations (aligned with those found in [5]), seem to suggest
that colorectal adenomas, independently of their size or degree of dysplasia, and even hyper-
plastic polyps, (both with reduced potential to make progress towards cancer), still feature a
relatively high number of subclonal mutations combined into inefficient non-carcinogenic sig-
natures. Thus, early steps of colorectal cancer could be characterised by highly dynamic genetic
changes until an efficient neoplastic signature, giving rise to an infiltrating carcinoma, is gener-
ated. Due to the limited number of patients analysed we cannot yet generalize whether all be-
nign lesions carry a high mutational load. This may also apply to the observation that
mutations found in adenomas do not coincide with those found in synchronous adenocarcino-
ma specimens in the same patient, a finding that is supported by data from other laboratories
[5]. The individual characterisation of these precise mutational signatures controlling tumour
dynamics at specific stages of the disease may serve in the near future as an indicator for the de-
velopment of specific combination therapies.
Materials and Methods
Ethics statement
All human samples used in this study were collected under a written informed consent form
that was appropriately signed and authorized by each patient and the doctor(s) involved and
approved by the CEIC (Comité Ético de Investigación Clínica, Cantabria). We kept the original
records under specific restrictive conditions to fulfil the current legal requirements. All pro-
cesses were conducted and approved following the specific recommendations of the CEIC.
Patients and samples
Nine freshly frozen colorectal samples taken from two previously untreated patients by endo-
scopic resection were selected for whole exome sequencing. Samples from Patient 1 (Fig. 1)
consisted of: a) normal mucosa, b) adenomatous polyp (30 cm), c) adenomatous polyp (90 cm)
and d) adenocarcinoma. Samples from Patient 2 (Fig. 2) consisted of: a) normal mucosa, b) hy-
perplastic polyp, c) adenomatous polyp, d) adenomatous polyp and e) adenocarcinoma. Fur-
ther information is provided in S1 and S5 Tables. All cases were reviewed by a panel of three
pathology specialists and lesions were graded following standard criteria [8].
Genomic DNA extraction, quantification, exome enrichment and
sequencing
Purified genomic DNA (3 μg) was extracted from snap-frozen (fresh) samples using standard
procedures. Briefly, PBS-washed samples, centrifuged and lysed using “Tissue and cell lysis so-
lution” buffer for the MasterPure kit, complemented by proteinase K (5 μl/100 μl buffer) (Epi-
center), shaking overnight at 56°C. DNA was extracted using phenol/chloroform/isoamyl
alcohol (in proportions of 25:24:1, respectively) in a fast Lock Gel Light Eppendorf tube
(Eppendorf), then washed and precipitated. Genomic DNA was quantified using a Qubit ds
DNA BR assay kit and a Qubit 2.0 fluorometer (Invitrogen) following the manufacturer’s in-
structions. Genomic DNA (3 μg) was then enriched in each case for protein coding sequences
using the in-solution exome capture SureSelect Human All Exon 50 Mb kit (Agilent
Genetic Heterogeneity of Synchronic Colorectal Tumors
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Fig 3. Mutation analyses of patients 3 and 4. Scheme showing an approximated representation of the location of each lesion analysed in patient-3 (A) and
patient-4 (B). The distance (*, in cms) from the pectineal line (red dots) is shown. C), D) Mutational index (number of mutations/Mb) found in the indicated
sample from the primary NGS analysis. H&E pictures are representative of each lesion studied by NGS. Tables below show a selection of genes with
oncogenic potential found mutated in the primary analyses of patient-3 (E) and patient 4 (F). Chrom: chromosome; %mutated: percentage of mutant
nucleotide found in the corresponding gene within the same sample.
doi:10.1371/journal.pone.0119946.g003
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Table 1. Clinical description of the samples analysed.
PATIENT SEX AGE SAMPLE SAMPLE NAME DIAGNOSTIC GRADE OF
DYSPLASIA
SIZE
(CMS)
MACROSCOPIC
DESCRIPTION
LOCALIZATION
(FROM
PECTINEAL
LINE)
1 FEMALE 82 N1E073 normal mucosa-1 normal mucosa N/A N/A healthy mucosa
without any macro-
or microscopic
alteration
50 cm
(descendent
colon)
1 FEMALE 82 N1E074 Adenoma-30 adenomatous
polyp
Tubular
adenoma with
moderate
dysplasia
0,8 Semi-pedunculated
polyp
30 cm (sigma)
1 FEMALE 82 N1E075 Adenoma-90 adenomatous
polyp
Tubular
adenoma
showing
moderate
dysplasia with
superﬁcial
focal severe
dysplasia
0,8 Semi-pedunculated
polyp
90 cm (ascendent
colon)
1 FEMALE 82 N1E076 Adenocarcinoma-
1
adenocarcinoma:
poorly
differentiated
N/A 5
(length)
stenotic and
ulcerated
circumferential
mass
7 cm (rectum)
2 MALE 82 N2E079 normal mucosa-2 normal mucosa N/A N/A healthy mucosa
without any macro-
or microscopic
alteration
50 cm
(descendent
colon)
2 MALE 82 N2E069 hyperplastic
polyp-2
hyperplastic polyp N/A 0,3 sessile polyp cecum
2 MALE 82 N2E092 Adenoma/Hyper-
2
adenomatous
polyp with
hyperplastic
mucosa
Tubular
adenoma
mostly showing
mild dysplasia
with focal
moderate
dysplasia
0,2 sessile polyp 20 cm (sigma)
2 MALE 82 N2E070 Adenoma-2 adenomatous
polyp
Tubular
adenoma
mostly showing
mild dysplasia
with focal
moderate
dysplasia
0,5 sessile polyp 30 cm
(descendent
colon)
2 MALE 82 N2E072 Adenocarcinoma-
2
adenocarcinoma:
Well differentiated
N/A 6
(length)
ulcerated,
circumferencial and
friable mass (3/
4ths of the rectal
lumen)
4 cm (rectum)
3 MALE 71 N3J876 normal mucosa-3 normal mucosa N/A N/A healthy mucosa
without any macro-
or microscopic
alteration
50 cm
(descendent
colon)
3 MALE 71 N3J874 Adenoma-rectum adenomatous
polyp
Tubular
adenoma
mostly showing
focal severe
dysplasia
0,5 pedunculated polyp 2 cm (rectum)
(Continued)
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Technologies), following the manufacturer’s protocol. The captured targets were subjected to
massively parallel sequencing using the Illumina HiSeq 2000 Analyzer (Illumina) with the
paired-end 2 × 75 bp read option, in accordance with the manufacturer’s instructions. Exome
capture and massively parallel sequencing were performed at the Spanish National Genome
Analysis Centre (CNAG, Barcelona, Spain). The raw data from this study have been deposited
in the NIH Short Read Archive (SRA) under accession number SRP040626.
Sequence mapping and identification of tumour variants
These methods have been described elsewhere [6]. Briefly, base calling and quality control were
performed in the Illumina RTA sequence analysis pipeline. Sequence reads were trimmed up
to the first base with a quality of more than 10. Mapping to human genome build hg19
(GRCh37) was done with GEM, allowing up to 4 mismatches [9]. Reads not mapped by GEM
(~4% of them) were subjected to a final round of mapping with BFAST [10]. Results were
merged and only uniquely mapping non-duplicate read pairs were used for subsequent analy-
ses. The SAMtools suite [11] with default settings was used to call SNVs and short INDELS.
Variants identified in regions with low mapability [12], with a read depth of< 10 or a strand
bias probability of< 0.001 were filtered out. Variants were annotated and effects predicted
with ANNOVAR [13] and snpEff [14], including information from dbSNP build 135 [15], the
1000 Genomes Project [16], the Exome Variant Server (NHLBI GO Exome Sequencing Project
(ESP), Seattle, WA; http://evs.gs.washington.edu/EVS/) and an internal database of sequence
variants identified in a set of> 100 control samples. Tags were added for positions with high
strand bias, high tail distance bias, a read depth of< 10 and those in low mapability regions.
Table 1. (Continued)
PATIENT SEX AGE SAMPLE SAMPLE NAME DIAGNOSTIC GRADE OF
DYSPLASIA
SIZE
(CMS)
MACROSCOPIC
DESCRIPTION
LOCALIZATION
(FROM
PECTINEAL
LINE)
3 MALE 71 N3J873 Adenoma-33 adenomatous
polyp
Tubular
adenoma
mostly showing
mild dysplasia
1 pedunculated polyp 33 cm (sigma:
from anal margin)
3 MALE 71 N3J872 Adenocarcinoma-
3
adenocarcinoma N/A 5
(length)
stenotic and
ulcerated
circumferential
mass
65 cm (hepatic
angle)
4 MALE 62 N4J881 normal mucosa-4 normal mucosa N/A N/A healthy mucosa
without any macro-
or microscopic
alteration
50 cm
(descendent
colon)
4 MALE 62 N4J878 Adenoma-4B adenomatous
polyp
Tubular
adenoma
mostly showing
mild dysplasia
0,8 Semi-pedunculated
polyp
80 cm (ascendent
colon)
4 MALE 62 N4J879 Adenoma-4C adenomatous
polyp
Tubular
adenoma
mostly showing
mild dysplasia
0,6 Semi-pedunculated
polyp
30 cm
4 MALE 62 N4J877 Adenocarcinoma-
4
adenocarcinoma N/A 8 Ulcerated
circumferential
mass. Occupies 1/
2 of the rectal
lumen
cecum
doi:10.1371/journal.pone.0119946.t001
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Fig 4. Distribution of mutations detected in the primary analysis. A). Percentage of the indicated
mutations detected in the primary analysis. B) Percentage of mutations in CpG dimers.
doi:10.1371/journal.pone.0119946.g004
Table 2. Number of unique amino-acid changing mutations found in the primary analysis.
PATIENT PATIENT
SAMPLE
DATA SOURCE MUTs* MUT.
INDEX
MUTs INVERSE
ANALISYS**
MUT. INDEX
(N)
1 N1E074 Adenoma-90 vs. normal mucosa-1 56 1,87 2 0,07
1 N1E075 Adenoma-30 vs. normal mucosa-1 93 3,10 3 0,10
1 N1E076 Adenocarcinoma 1 vs. normal mucosa-
1
84 2,80 4 0,13
2 N2E069 Hyperplastic-P vs. normal mucosa-2 35 1,17 2 0,07
2 N2E092 Adenoma/Hyper vs. normal mucosa-2 45 1,50 6 0,20
2 N2E070 Adenoma 2 vs. normal mucosa-2 74 2,47 4 0,13
2 N2E072 Adenocarcinoma 2 vs. normal mucosa-
2
130 4,33 4 0,13
3 N3J874 Adenoma-rectum vs normal mucosa-3 74 2,47 9 0,30
3 N3J885 Adenoma-33 vs normal mucosa-3 33 1,10 7 0,23
3 N3J872 Adenocarcinoma-3 vs normal mucosa-3 155 5,17 14 0,47
4 N4J878 Adenoma-4B vs normal mucosa-4 33 1,10 5 0,17
4 N4J879 Adenoma-4C vs normal mucosa-4 25 0,83 8 0,27
4 N4J877 Adenocarcinoma-4 vs normal mucosa-4 58 1,93 9 0,30
MUTs*: Number of amino-acid changing mutations in each lesion vs. normal mucosa, MUT. INDEX: Number of mutations/Mb (Exome) in the colorectal
lesion, MUTs INVERSE ANALYSIS**: Number of amino-acid changing mutations found in normal mucosa vs. each lesion, MUT. INDEX (N): Number of
mutations/Mb (Exome) in normal mucosa.
doi:10.1371/journal.pone.0119946.t002
Genetic Heterogeneity of Synchronic Colorectal Tumors
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For tumour-normal comparison, the probability of a Fisher's exact test was calculated for posi-
tions with different genotypes in the two samples.
Detection of subclonal mutations
To identify mutations present in subclonal populations inside the tumours we used a slightly dif-
ferent analysis pipeline. Sequence reads were aligned to the human reference genome (GRCh37)
using BWA, and the alignment was consequently cleaned using SAMtools and Picard tools for
mating coordinate fixing and PCR duplicate flagging. Finally, GATK indel realigner was used to
realign locally around small insertion and deletions (indels). A program specifically written in-
house named RAMSES (“Realignment Assisted Minimum Evidence Spotter”; Ignacio Varela,
manuscript in preparation) was used to identify coordinates with a minimum value of 2, that
were independently aligned with BLAT, and that gave high-quality reads reporting differences
from the reference genome in the tumour sample and absolutely no evidence of the same change
in the corresponding normal sample. Additionally, mutations near DNA repeats, present in the
dbSNP and 1000 Genomes databases, or reported near the end of the reads, were removed. The
functional consequence of the mutations was annotated using the Ensembl perl API (Ensembl
database, release 69) and only coding mutations were retained.
Secondary analysis by 454 Roche
114 candidate variants from patients 1 and 2 were validated by targeted resequencing using the
GS Junior System (Roche). ~300 bp amplicons around the identified mutations were generated,
to which specific adaptors were ligated (S3 Table). A pooled, barcoded mixture of amplicons
was sequenced using the 454-Junior platform (Roche). The reads were aligned against the
human reference genome (GRCh37) using the BWA-SW algorithm. SAMtools was used subse-
quently to generate bam and pileup files, which were parsed using scripts written in-house.
Only those positions with a minimum coverage of 20 in both tumour and normal samples
were considered. Mutations with at least 5 independent mutant reads corresponding to a mini-
mum of 1% of the total number of reads at that position in the tumour sample, but with no mu-
tant reads present in the corresponding normal sample, were considered to be validated.
Supporting Information
S1 Fig. Secondary analysis. Percentage of validated mutations in a selection of 92 genes from
patients 1 and 2. MP (Mutational percentage): percentage of mutated reads for each mutation.
MP>15%: Refers to a mutation found in 15% or more of the total number of reads in the same
genomic position. Blue: Confirmed mutations; Red: Not confirmed mutations.
(TIF)
S2 Fig. Distribution of validated mutations. A). Percentage of validated mutations from the
secondary analysis. B) Percentage of mutations in CpG. p shows the statistical significance in
Fisher´s test.
(TIF)
S1 Table. Mapping and coverage metrics. tROI: Bases that are able to be captured into the ge-
nome region that is targeted in the experiment. Specificity: The percentage of non-target bp se-
quenced among all bases sequenced. Enrichment: Efficiency of recovery for targeted bp in
relation to the efficiency of recovery for non-targeted bp, C15: percentage of bases with at least
15X coverage. Mean_cov: mean coverage of the targeted region. Median_cov: median coverage
of the targeted region.
(XLS)
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S2 Table. Validation panel.Wt Allele: Wild type nucleotide. Mut Allele: Mutated nucleotide.
Ref. Reads: Number of reads of the Wt Allele. Mut reads: Number of reads of the Wt Allele.
TumorA, C, G or T: Number of reads of each nucleotide.
(XLS)
S3 Table. Oligonucleotides used for validation analysis.
(XLS)
S4 Table. Nucleotide context in validated mutations.
(XLS)
S5 Table. Unique mutations (SNVs) found in this study with potential to provoke amino
acid changes. Ref_base: Wild type nucleotide. Mut_base: Mutated nucleotide. Reads_A, C, G
or T: Number of reads of each nucleotide. In CpG: the nucleotide is located in a CpG island.
Gene ID: Gene name. Transcript ID: Transcript name. c.Annot: Mutation in the cDNA. pAn-
not: Mutations in protein. Interpretation: Mutations effect.
(XLS)
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